Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Clinical Oncology

• Publication date

  2009-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2008.19.2963PMID 19332726PMCID PMC2690393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.

  2009cited by this paper
• Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study

  2008influential reference
• Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)

  2008cited by this paper
• Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer

  2008cited by this paper
• A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer

  2008cited by this paper
• Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.

  2008cited by this paper
• A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer.

  2008cited by this paper
• Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).

  2008cited by this paper
• Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

  2008cited by this paper
• Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.

  2008cited by this paper
• Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

  2007cited by this paper
• Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.

  2007cited by this paper
• The Therapeutic Efficacy of Anti–Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice

  2007cited by this paper
• Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics

  2007cited by this paper
• A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer

  2007cited by this paper
• Single-Institution Experience with Pemetrexedand Bevacizumab as Salvage Therapy in AdvancedNon–Small-Cell Lung Cancer

  2007cited by this paper
• Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

  2007cited by this paper
• Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer.

  2007cited by this paper
• A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non–Small Cell Lung or Esophageal Cancer

  2007cited by this paper
• Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.

  2006cited by this paper
• A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours

  2006cited by this paper
• Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.

  2006cited by this paper
• Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group.

  2006cited by this paper
• Pemetrexed (Alimta®, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single‐agent trial

  2006cited by this paper
• Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.

  2006cited by this paper
• Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.

  2005cited by this paper
• The ALPI Trial: The Italian/European Experience with Adjuvant Chemotherapy in Resectable Non–Small Lung Cancer

  2005cited by this paper
• Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.

  2005cited by this paper
• Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer

  2005cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004cited by this paper
• Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.

  2003cited by this paper
• A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.

  2003cited by this paper
• Developmental chemotherapy and management of recurrent ovarian cancer.

  2003cited by this paper
• Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

  2003cited by this paper
• Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Resistant Ovarian Cancer: A Gynecologic Oncology Group Study

  2002cited by this paper
• Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

  2002cited by this paper
• Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.

  2002cited by this paper
• Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first‐line therapy in patients with advanced nonsmall cell lung carcinoma

  2001cited by this paper
• Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

  2001cited by this paper
• Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

  2001cited by this paper
• Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.

  2000cited by this paper
• Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial.

  2000cited by this paper
• Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.

  1999cited by this paper
• Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.

  1999cited by this paper
• Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.

  1999cited by this paper
• Optimal flexible designs in phase II clinical trials.

  1998cited by this paper
• Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.

  1998cited by this paper
• Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.

  1998cited by this paper
• Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group.

  1998cited by this paper
• Role of folate receptor and reduced folate carrier in the transport of 5‐methyltetrahydrofolic acid in human ovarian carcinoma cells

  1998cited by this paper
• Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

  1998cited by this paper
• LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

  1997influential reference
• Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines

  1997cited by this paper
• Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.

  1996cited by this paper
• Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.

  1994cited by this paper
• Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.

  1992cited by this paper

• LAMC3 interference reduces drug resistance of carboplatin-resistant ovarian cancer cells

  2025cites this paper
• Homologous recombination deficiency testing in ovarian cancer: the diagnostic experience of a referral Italian institution

  2025cites this paper
• Metabolism-associated marker gene-based predictive model for prognosis, targeted therapy, and immune landscape in ovarian cancer: an integrative analysis of single-cell and bulk RNA sequencing with spatial transcriptomics

  2025cites this paper
• Gαi2 Protein Inhibition Blocks Chemotherapy- and Anti-Androgen-Induced Prostate Cancer Cell Migration

  2024cites this paper
• Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine

  2023cites this paper
• Advancements in protein glycosylation biomarkers for ovarian cancer through mass spectrometry-based approaches

  2023cites this paper
• The GOG Foundation, Inc. Developmental Therapeutics Committee Phase I & Phase II Studies

  2023cites this paper
• Molecular mechanisms of cisplatin resistance in ovarian cancer

  2023cites this paper
• In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study

  2023cites this paper
• Spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors.

  2023cites this paper
• Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients

  2022cites this paper
• BI 2536 induces gasdermin E-dependent pyroptosis in ovarian cancer

  2022cites this paper
• Optimizing regional chemotherapy for epithelial ovarian cancer

  2022cites this paper
• Long-term ovarian cancer survivors: spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface

  2022cites this paper
• The Anti-Tumor Efficacy of Verbascoside on Ovarian Cancer via Facilitating CCN1-AKT/NF-κB Pathway-Mediated M1 Macrophage Polarization

  2022cites this paper
• Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates

  2022cites this paper
• Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial

  2022cites this paper
• Neoadjuvant Chemotherapy Modulates the Tumor Microenvironment in High-Grade Serous Ovarian Cancer

  2021cites this paper
• Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies

  2021cites this paper
• Single-Cell RNA-Sequencing Portraying Functional Diversity and Clinical Implications of IFI6 in Ovarian Cancer

  2021cites this paper
• Platinum-Pemetrexed Chemotherapy for Recurrent Ovarian Cancer (ROC): A Single Center Experience

  2021cites this paper
• Application of Bioinformatics Analysis to Identify Important Pathways and Hub Genes in Ovarian Cancer Affected by WT1

  2021cites this paper
• Radiomics Analysis of PET and CT Components of 18F-FDG PET/CT Imaging for Prediction of Progression-Free Survival in Advanced High-Grade Serous Ovarian Cancer

  2021cites this paper
• Cancer of the ovary, fallopian tube, and peritoneum: 2021 update

  2021cites this paper
• Single-cell analysis revealed that IL4I1 promoted ovarian cancer progression

  2021cites this paper
• Ovarian Cancer: Primary Advanced and Recurrent Disease

  2021cites this paper
• Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research

  2021cites this paper
• Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.

  2020cites this paper
• Evaluation of pemetrexed in the treatment of epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: a retrospective study

  2020cites this paper
• ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer

  2020cites this paper
• Multi-kinase targeted therapy as a promising treatment strategy for ovarian tumors expressing sfRon receptor

  2020cites this paper
• Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

  2020cites this paper
• Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.

  2020cites this paper
• A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells

  2020cites this paper
• Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer

  2020cites this paper
• Biodegradable Mg Implants Suppress the Growth of Ovarian Tumor.

  2020cites this paper
• Subcellular localization of FANCD2 is associated with survival in ovarian carcinoma

  2020influential citation
• Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma

  2020cites this paper
• The role of CSDE1 in translational reprogramming and human diseases

  2020cites this paper
• Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study

  2020cites this paper
• Multi-Targeting by β-Elemene and Its Anticancer Properties: A Good Choice for Oncotherapy and Radiochemotherapy Sensitization

  2020cites this paper
• Dihydrofolate reductase as a predictor for poor response to platinum-based chemotherapy in epithelial ovarian cancer.

  2019cites this paper
• siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer

  2019cites this paper
• Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers

  2019cites this paper
• Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer.

  2019cites this paper
• Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis.

  2019cites this paper
• Gene networks and expression quantitative trait loci associated with platinum-based chemotherapy response in high-grade serous ovarian cancer

  2019cites this paper
• A panel of three oxidative stress-related genes predicts overall survival in ovarian cancer patients received platinum-based chemotherapy

  2018cites this paper
• Cancerous inhibitor of protein phosphatase 2A regulates cisplatin resistance in ovarian cancer.

  2018cites this paper
• Use of apatinib combined with pemetrexed for advanced ovarian cancer

  2018cites this paper
• Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement

  2018cites this paper
• Insights into Impact of DNA Copy Number Alteration and Methylation on the Proteogenomic Landscape of Human Ovarian Cancer via a Multi-omics Integrative Analysis*

  2018cites this paper
• MiR‐34c/SOX9 axis regulates the chemoresistance of ovarian cancer cell to cisplatin‐based chemotherapy

  2018cites this paper
• Low expression of KCNN3 may affect drug resistance in ovarian cancer

  2018cites this paper
• Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer

  2018cites this paper
• IGHG1 promotes motility likely through epithelial-mesenchymal transition in ovarian cancer.

  2018cites this paper
• Microarray‐based identification of genes associated with prognosis and drug resistance in ovarian cancer

  2018cites this paper
• BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors

  2018cites this paper
• Management and Treatment of Recurrent Epithelial Ovarian Cancer.

  2018cites this paper
• Epithelial ovarian, fallopian tube, and primary peritoneal cancer

  2018cites this paper
• Radiomics: a Novel CT-Based Method of Predicting Postoperative Recurrence in Ovarian Cancer

  2018cites this paper
• Interobserver Agreement of the Histopathological Diagnosis

  2018cites this paper
• Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth.

  2018cites this paper
• The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review

  2018cites this paper
• Dynamic visualization of multi-level molecular data: The Director package in R

  2018cites this paper
• miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1

  2018cites this paper
• Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers

  2018cites this paper
• Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients

  2017cites this paper
• Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum

  2017cites this paper
• Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer

  2017cites this paper
• Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells*

  2017cites this paper
• A 19F NMR probe for the detection of β-galactosidase: simple structure with low molecular weight of 274.2, "turn-on" signal without the background, and good performance applicable in cancer cell line.

  2017cites this paper
• PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?

  2017cites this paper
• DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer

  2017cites this paper
• Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2017cites this paper
• RETRACTED ARTICLE: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy

  2017cites this paper
• Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.

  2017cites this paper
• Investigating the role of microRNAs and extracellular vesicles in cisplatin resistance in ovarian cancer

  2016cites this paper
• Recurrent Ovarian Cancer — Basic Knowledge, Current Management, and Future Directions

  2016cites this paper
• Manual epithelial Ovarian Cancer : Management of advanced disease

  2016cites this paper
• Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum‐sensitive ovarian, fallopian tube, or primary peritoneal cancer

  2016cites this paper
• [Molecular Mechanisms of Carcinogenesis of Epithelial Ovarian Cancers].

  2016cites this paper
• Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients

  2016cites this paper
• SIAH 2 expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer

  2016cites this paper
• miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance

  2016cites this paper
• Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.

  2016cites this paper
• Downregulation of vimentin expression increased drug resistance in ovarian cancer cells

  2016cites this paper
• Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells.

  2015cites this paper
• Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer

  2015cites this paper
• Genetic and molecular analyses reveal G6PC as a key element connecting glucose metabolism and cell cycle control in ovarian cancer

  2015cites this paper
• Knockdown of eIF 4 E suppresses cell proliferation , invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells

  2015cites this paper
• Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.

  2015cites this paper
• Interferon alpha-inducible protein 27 promotes epithelial-mesenchymal transition and induces ovarian tumorigenicity and stemness.

  2015cites this paper
• Managing the patient

  2015cites this paper
• PPP2R1A mutations in gynaecologic cancers: functional characterization and use in the genomic classification of tumours

  2015cites this paper
• REGULATION OF THE OXIDATIVE STRESS RESPONSE BY ARID1A

  2015cites this paper
• FRS2 Is an Oncogene in High Grade Ovarian Cancer

  2015cites this paper
• Down-regulation of Ras-related Protein Rab 5C-dependent Endocytosis and Glycolysis in Cisplatin-resistant Ovarian Cancer Cell Lines*

  2014cites this paper
• Vintafolide: a novel targeted agent for epithelial ovarian cancer.

  2014cites this paper
• Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer

  2014cites this paper